Clinical trial
A Randomized, Placebo-Controlled, Double-Blind and Multi-Centre Phase II Clinical Trial：Efficacy and Safety of Jia Shen Tablets in the Treatment of Coronary Heart Disease Complicating Chronic Heart Failure (Syndrome of Yang Qi Deficiency With Blood Stasis)
NCT06669169 is registered in ClinicalTrials.gov with Tasly Pharmaceutical Group Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-Controlled, Double-Blind and Multi-Centre Phase II Clinical Trial：Efficacy and Safety of Jia Shen Tablets in the Treatment of Coronary Heart Disease Complicating Chronic Heart Failure (Syndrome of Yang Qi Deficiency With Blood Stasis)
- Lead sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 31, 2025
- Completion date
- December 31, 2026
- Enrollment
- 288 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.